Search hospitals

>

Michigan

>

Grand Rapids

Helen DeVos Children's Hospital at Spectrum Health

Claim this profile

Grand Rapids, Michigan 49503

Global Leader in Cancer

Global Leader in Neuroblastoma

Conducts research for Brain Tumor

Conducts research for Acute Lymphoblastic Leukemia

Conducts research for Solid Tumors

333 reported clinical trials

8 medical researchers

Photo of Helen DeVos Children's Hospital at Spectrum Health in Grand RapidsPhoto of Helen DeVos Children's Hospital at Spectrum Health in Grand RapidsPhoto of Helen DeVos Children's Hospital at Spectrum Health in Grand Rapids

Summary

Helen DeVos Children's Hospital at Spectrum Health is a medical facility located in Grand Rapids, Michigan. This center is recognized for care of Cancer, Neuroblastoma, Brain Tumor, Acute Lymphoblastic Leukemia, Solid Tumors and other specialties. Helen DeVos Children's Hospital at Spectrum Health is involved with conducting 333 clinical trials across 584 conditions. There are 8 research doctors associated with this hospital, such as Kathleen J. Yost, Troy Quigg, DO, David Hoogstra, and Deanna Mitchell, MD.

Area of expertise

1

Cancer

Global Leader

Helen DeVos Children's Hospital at Spectrum Health has run 52 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Neuroblastoma

Global Leader

Helen DeVos Children's Hospital at Spectrum Health has run 45 trials for Neuroblastoma. Some of their research focus areas include:

MYC positive
Stage IV
Stage I

Top PIs

Clinical Trials running at Helen DeVos Children's Hospital at Spectrum Health

Multiple Myeloma

Lung Cancer

Melanoma

Acute Lymphoblastic Leukemia

Neuroblastoma

Leukemia

Cutaneous Melanoma

Testicular cancer

Cancer

Breast Cancer

Image of trial facility.

Drug Combinations

for Multiple Myeloma

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which is given after initial treatment to help keep the cancer from coming back. There are three combinations of four different drugs being studied. Bortezomib is one of the drugs that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide works by helping bone marrow to produce normal blood cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Patients receive 1 of 3 combinations of these drugs for treatment to determine which combination of study drugs works better to shrink and control multiple myeloma.

Recruiting

2 awards

Phase 3

21 criteria

Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Recruiting

2 awards

Phase 3

32 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Helen DeVos Children's Hospital at Spectrum Health?

Where is Helen DeVos Children's Hospital at Spectrum Health located?

Who should I call to ask about financial aid or insurance network?

What insurance does Helen DeVos Children's Hospital at Spectrum Health accept?

What awards or recognition has Helen DeVos Children's Hospital at Spectrum Health received?